EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Hodgkin- and non-Hodgkin lymphoma



Treatment of Hodgkin- and non-Hodgkin lymphoma



Orvosi Hetilap 144(49): 2429-2431, December 7




(PDF 0-2 workdays service: $29.90)

Accession: 035980498

Download citation: RISBibTeXText



Related references

Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. Journal of Clinical Oncology 19(7): 2026-2032, 2001

Presence of Epstein-Barr viral DNA and EBV latent gene products in Hodgkin and non-Hodgkin lymphoma High expression of EBV-DNA sequences in non-Hodgkin lymphoma with variable numbers of CD30-positive cells. Lambert, W C , Giannotti, B , van Vloten, W A NATO ASI Series Series A Life Sciences; Basic mechanisms of physiologic and aberrant lymphoproliferation in the skin 205-216, 1994

Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL. International Journal of Cancer 106(5): 706-712, 2003

Hodgkin's disease, follicular non-Hodgkin's lymphoma and a high grade B cell non-Hodgkin's lymphoma in the same patient. Leukemia & Lymphoma 18(1-2): 185-187, 1995

BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 54(9): 2081-2082, 2014

Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96(4): 1280-1286, 2000

Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience. Advances in Clinical and Experimental Medicine 24(5): 783-789, 2016

Treatment of early and intermediate stage Hodgkin's lymphoma in the German Hodgkin's Lymphoma Study Group. Annals of Oncology 13 Suppl 1: 84-85, 2002

Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group. Klinicka Onkologie 29(5): 342-346, 2016

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Annals of Oncology 22(3): 681-688, 2011

New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. Journal of Clinical Oncology 20(1): 221-230, 2002

Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. Quarterly Journal of Nuclear Medicine 45(3): 269-273, 2002

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101(2): 420-424, 2003

MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology 12(7): 1366-1374, 1994

Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 23(30): 7555-7564, 2005